Type 2 diabetes is growing rapidly and is one of the world’s most prevalent chronic conditions. Weight-loss drugs, such as GLP-1s, will not eliminate the need for other tools people use to manage diabetes, such as continuous glucose monitoring (CGM) systems.
Data from a September analysis of these weight-loss drugs and of continuous glucose monitoring (including our FreeStyle Libre CGM systems) show a growing number of people are using these tools together in their treatment of diabetes.
In our analysis, we also found that FreeStyle Libre sensor adherence — in other words, the number of days a sensor is worn — is higher for those who also use GLP-1 therapy.
Share